May 9, 2026 Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
April 23, 2026 Title: Pretreatment Immune Profiles Linked to Immune-Related Adverse Events May Guide Personalized Management Strategies
